CAS: 59-00-7; 4,8-Dihydroxyquinoline-2-Carboxylic Acid

上下游产品

methyl 4-hydroxy-8-methoxyquinoline-2-carboxylate 8-methoxy-4-oxo-1,4-dihydro-quinoline-2-carboxylic acid ethyl ester 3-hydroxykynurenine 4-hydroxy-2-methylquinoline4,8-dihydroxyquinoline -(R)-glutamic acid di-n-pentylamide γ-benzyl esterN-(4',8'-dihydroxy-2'-quinolyl)carbonyl-(R)-glutamic acid di-n-pentylamide γ-benzyl ester toluene-4-sulfonic acid 4-oxo-1,4-dihydro-quinolin-8-yl ester 4-methoxyquinolin-8-yl 4-methylbenzenesulfonate

📜4-羟基-8-甲氧喹啉-2-甲酸乙酯置于磷酸,Potassium Iodide体系中,化学反应生成 4,8-二羟基喹啉-2-甲酸
参考文献:A Convenient Synthesis Of Xanthurenic Acid
标题:A Convenient Synthesis Of Xanthurenic Acid
摘要:
DOI:10.1021/jo01143A010

专利信息

专利号:US-2004110228-A1
优先权日:2002-04-01
标 题:Combinatorial organic synthesis of unique biologically active compounds
发明人：MCALPINE SHELLI R; TAYLOR RACHEL E; BOLLA MEGAN L; SEGALL ANCA M
摘要:The invention provides a method for making a combinatorial library of cyclic compounds, such as Holliday junction-trapping compounds, comprising the steps of (a) obtaining a plurality of trimers according to the generic structure X 1- X 2- X 3 , wherein X 1 , X 2 and X 3 can be independently any naturally or nonnaturally occurring amino acids or peptidomimetics thereof; (b) optionally coupling a spacer S to the trimer at either end; (c) cyclizing two trimers or trimer-spacer conjugates in a head-to-tail orientation; thereby obtaining a combinatorial library of compounds, wherein the library does not include an unmodifed or naturally occurring Holliday Junction-trapping compounds. The invention additionally provides methods macrocyclic compounds that are synergimycin derivatives.

专利号:US-2005080260-A1
优先权日:2003-04-22
标 题 :Preparation of prodrugs for selective drug delivery
发明人：MILLS RANDELL L; WU GUO-ZHANG
摘要:Synthesis of a chemical compound having the formula A-B-C that may serve for applications such as drug delivery where A is a chemiluminescent, moiety, B is a photochromic moiety, and C is a biologically active moiety where A-B-C may serve as a prodrug. Novel synthetic methods of the present invention to form the prodrug comprised the steps of (1) forming a benzophenone, (2) forming a diaryl ethylene, (3) attaching a phthalimide moiety to at least one of the aryl groups of the ethylene to form a phthalimide-ethylene conjugate, (4) condensing two ethylene-phthalimide conjugates to form a phthalimide-pentadiene conjugate, (5) converting the phthalimide to the phthalhydrazide by reaction with hydrazine to form a carrier compound according to the present invention, and (6) reacting the carrier compound with an nucleophilic moiety of the drug to form the corresponding prodrug. Alternatively the carrier can be prepared by using the halo-substituted diaryl ethylene to make the corresponding cationic leuco dye-like compound with known methods. The cationic compound then is protected by reacting with a nucleophile and coupled with the aminophathalimide by palladium-catalyzed amination to form the protected phthalimide-pentadiene conjugate. The latter is refluxed with hydrazine to convert its phthalimide to the phthalhydrazide and acidified to give the carrier. An additional aspect of the present invention relates to the use of these compounds as antiviral agents for the treatment of viral infections such as HIV and as anticancer agents for the treatment of cancers such as bowel, lung, and breast cancer.

专利号:US-9453037-B2
优先权日:2011-07-28
标 题 :Methylphenidate-prodrugs, processes of making and using the same
发明人：GUENTHER SVEN; CHI GUOCHEN; BERA BINDU; MICKLE TRAVIS; BERA SANJIB
权利人:KEMPHARM INC; KEMPHARM INC
摘要:The present technology is directed to prodrugs and compositions for the treatment of various diseases and/or disorders comprising methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof. In some embodiments, the conjugates further include at least one linker. The present technology also relates to the synthesis of methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof or combinations thereof.

专利号:US-2010273787-A1
优先权日:2007-11-15
标题:Kynurenine-aminotransferase inhibitors
发明人：SCHWARCZ ROBERT; KAJII YASUSHI; ONO SHIN-ICHIRO
权利人:SCHWARCZ ROBERT; KAJII YASUSHI; ONO SHIN-ICHIRO
摘要:Compounds of formula (I): prodrug derivatives and/or pharmaceutically acceptable salt thereof, selectively inhibit the enzyme kynurenine aminotransferase, thereby reducing the synthesis of kynurenic acid. The compounds are used for the treatment of psychiatric and neurological diseases which benefit from an increase in glutamatergic and/or cholinergic neurotransmission, such as schizophrenia, depression, bipolar illness, anxiety and Alzheimer's disease. Furthermore, the compounds of the invention are useful for stimulating attention, memory and other cognitive processes in normal individuals of any age, including children, adolescents and the elderly. Additionally, the compounds of the invention are also useful for treatment of patients suffering from malaria by preventing parasite gametogenesis and fertility based on reduction of xanthurenic acid formation from its bioprecursor 3-hydroxy kynurenine.

专利号:WO-2018191771-A1
优先权日:2017-04-18
标题 :Detection and treatment of congenital malformations
发明人：DUNWOODIE SALLY; SPARROW DUNCAN; STOCKER ROLAND; SHI HONGJUN
权利人:VICTOR CHANG CARDIAC RES INSTITUTE
摘要:The invention relates to a method of preventing or treating a congenital malformation in an unborn offspring of a subject, the method comprising administering to the subject a therapeutically effective amount of NAD or an intermediate of NAD synthesis.

专利号:US-8815936-B2
优先权日:2008-03-03
标题:Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders
发明人：GRANT ROSS STEWART; BRAIDY NADY; GUILLEMIN GILLES; SMYTHE GEORGE
权利人:GRANT ROSS STEWART; BRAIDY NADY; GUILLEMIN GILLES; SMYTHE GEORGE; NAD LIFE PTY LTD
摘要:Described is a composition for preventing or treating an oxidative stress related disease or condition in a subject. The disease or condition is characterized by the presence of excess oxidative compounds in the subject, and the composition includes a synergistic combination of therapeutically effective amounts of resveratrol to promote NAD + synthesis in the subject; a chelating agent to reduce production of additional oxidative compounds in the subject; and an antioxidant to minimize the oxidative activity in the subject.